Researchers at the University of Waterloo have developed a new system that could significantly speed up the discovery of new drugs and reduce the need for costly and time-consuming laboratory tests.
The new technology called Pattern to Knowledge (P2K) can predict the binding of biosequences in seconds and potentially reduce bottlenecks in drug research.
P2K uses artificial intelligence (AI) to leverage deep knowledge from data instead of relying solely on classical machine learning.
“P2K is a game changer given its ability to reveal subtle protein associations entangled in complex physiochemical environments and powerfully predict interactions based only on sequence data,” said Andrew Wong, professor, Systems Design Engineering, and Founding Director, Centre for Pattern Analysis and Machine Intelligence (CPAMI). “The ability to access this deep knowledge from proven scientific results will shift biological research going forward. P2K has the power to transform how data could be used in the future.”
Although a large amount of biological sequence data has been collected, extracting meaningful and useful knowledge hasn’t been easy. P2K algorithms tackle this challenge by disentangling multiple associations to identify and predict amino acid bindings that govern protein interactions. Since P2K is much faster than existing biosequence analysis software with almost 30 per cent better prediction accuracy, it could significantly speed up the discovery of new drugs. By drawing information from databases in the Cloud, P2K could predict how tumour proteins and potential cancer treatments would interact.
Although still in the early prototype stage, Professor Wong and his team have made the online P2K system available publicly to researchers to start identifying new bio-sequence interactions.
“Putting this AI technology in the hands of biomedical researchers will generate immediate results, which could be used for future scientific discoveries,” said Antonio Sze-To, research associate, Systems Design Engineering, and co-inventor of P2K.
Since it analyzes sequential data, the applicability of P2K isn’t limited to biomedical research. P2K could benefit the financial industry by making useful associations and predictions for smart trading or the cybersecurity sector by predicting the likelihood of a potential cyber attack.
The Latest on: Drug discovery
via Google News
The Latest on: Drug discovery
- High-Performance Cloud Speeds Drug Discovery And Moreon June 25, 2020 at 2:08 am
GridMarkets runs its rendering platform on Oracle Cloud Infrastructure, speeding production of ultraheavy workloads at scale.
- Sosei, AbbVie sign drug discovery deal worth up to $1 blnon June 25, 2020 at 1:03 am
Japan's Sosei Group Corp will collaborate with AbbVie Inc on a drug discovery partnership that could be worth up to $1 billion. Sosei shares soared 12.4% in Tokyo trading, compared with a 1.2% slide ...
- Sosei, AbbVie sign drug discovery deal worth up to $1 billionon June 25, 2020 at 12:44 am
Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. An expansion to four targets would put the total deal size "in a similar ballpark" to deals signed in 2019 ...
- Japan's Sosei Group signs $377 mln drug discovery deal with Abbvieon June 24, 2020 at 7:44 pm
Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday. S ...
- Cyclica banks $17M to decentralize drug discovery, speed drug developmenton June 24, 2020 at 7:15 am
In its own words, Cyclica wants to “create the biotech pipeline of the future,” and that means going beyond just five, 10 or 15 shots on goal. It wants to have hundreds—and eventually, thousands—of ...
- Small Molecule Drug Discovery Market Report Examines Analysis by Latest Trends, Growth Factors, Key Players and Forecast to 2028on June 24, 2020 at 4:45 am
Jun 24, 2020 (Market Insight Reports) -- This detailed market study covers small molecule drug discovery market growth potentials which can assist the stake holders to understand key trends and ...
- Cyclica raises $23 million to accelerate drug discovery with AIon June 23, 2020 at 10:00 pm
Cyclica, a startup developing an AI-powered platform for drug discovery, has secured $23 million in venture capital financing.
- TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilitieson June 23, 2020 at 1:52 pm
TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This fi ...
- Schrödinger expands COVID-19 drug discovery effortson June 23, 2020 at 4:48 am
Physics-based software platform developer Schrödinger (NASDAQ:SDGR) announces a "significant" expansion of its work to discover novel antivirals for COVID-19 under its partnership with a phila ...
via Bing News